← All trials
NCT03948464
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2019
- Primary completion
- Jul 31, 2021
- Completion date
- Jan 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 198
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BC Centre on Substance UseLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- Mayne PharmaCollaborator
- Vancouver FoundationCollaborator
- BC Centre on Substance UseSponsor investigator
- BC Centre on Substance UseOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.